U. Fritz Bredeek

Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

Antonella Castagna, Franco Maggiolo, Giovanni Penco et al. · The Journal of Infectious Diseases · 2014 · 329 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Antiviral Activity, Safety, and Pharmacokinetics/Pharmacodynamics of Tenofovir Alafenamide as 10-Day Monotherapy in HIV-1–Positive Adults

Peter Ruane, Edwin DeJesus, Daniel Berger et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2013 · 307 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Pre-Exposure Prophylaxis (PrEP) for HIV Infection: Results of a Survey of HIV Healthcare Providers Evaluating Their Knowledge, Attitudes, and Prescribing Practices

David Tellalian, Khalid Maznavi, U. Fritz Bredeek et al. · AIDS Patient Care and STDs · 2013 · 139 citations

Public Health, Preventive Medicine, Hiv Control +15

Gemini: A Noninferiority Study of Saquinavir/Ritonavir Versus Lopinavir/Ritonavir as Initial HIV-1 Therapy in Adults

Sharon Walmsley, Anchalee Avihingsanon, Jihad Slim et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2009 · 115 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial

Chloe Orkin, Jean‐Michel Molina, Eugènia Negredo et al. · The Lancet HIV · 2017 · 96 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +17